JP2023520399A5 - - Google Patents
Info
- Publication number
- JP2023520399A5 JP2023520399A5 JP2022559585A JP2022559585A JP2023520399A5 JP 2023520399 A5 JP2023520399 A5 JP 2023520399A5 JP 2022559585 A JP2022559585 A JP 2022559585A JP 2022559585 A JP2022559585 A JP 2022559585A JP 2023520399 A5 JP2023520399 A5 JP 2023520399A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cell
- targeting agent
- sequence
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026071149A JP2026123131A (ja) | 2020-03-31 | 2026-04-22 | ヒト抗ｃｄ３３抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003203P | 2020-03-31 | 2020-03-31 | |
| US63/003,203 | 2020-03-31 | ||
| PCT/US2021/025220 WO2021202770A2 (en) | 2020-03-31 | 2021-03-31 | Human anti-cd33 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026071149A Division JP2026123131A (ja) | 2020-03-31 | 2026-04-22 | ヒト抗ｃｄ３３抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520399A JP2023520399A (ja) | 2023-05-17 |
| JP2023520399A5 true JP2023520399A5 (enExample) | 2024-03-28 |
| JP7855521B2 JP7855521B2 (ja) | 2026-05-08 |
Family
ID=77929454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559585A Active JP7855521B2 (ja) | 2020-03-31 | 2021-03-31 | ヒト抗ｃｄ３３抗体及びその使用 |
| JP2026071149A Pending JP2026123131A (ja) | 2020-03-31 | 2026-04-22 | ヒト抗ｃｄ３３抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026071149A Pending JP2026123131A (ja) | 2020-03-31 | 2026-04-22 | ヒト抗ｃｄ３３抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12662546B2 (enExample) |
| EP (1) | EP4126248A4 (enExample) |
| JP (2) | JP7855521B2 (enExample) |
| CN (1) | CN115397515A (enExample) |
| CA (1) | CA3173205A1 (enExample) |
| WO (1) | WO2021202770A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| JP7840865B2 (ja) * | 2020-03-31 | 2026-04-06 | フレッド ハッチンソン キャンサー センター | キメラ抗原受容体ターゲティングｃｄ３３ |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| PE20241343A1 (es) * | 2021-10-15 | 2024-07-03 | Cytomx Therapeutics Inc | Complejo polipeptidico activable |
| AU2023289376A1 (en) * | 2022-06-22 | 2025-01-16 | Eli Lilly And Company | Human cd33 antibodies and glucocorticoid conjugates |
| CN121591894A (zh) * | 2024-08-23 | 2026-03-03 | 南京北恒生物科技有限公司 | 靶向cd33的抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004272607B2 (en) | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| WO2008007755A1 (en) | 2006-07-13 | 2008-01-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducer |
| EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| AR098743A1 (es) | 2013-12-13 | 2016-06-08 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| CN108064245A (zh) | 2015-04-17 | 2018-05-22 | 埃尔萨里斯生物技术公司 | 抗Tyro3抗体及其用途 |
| AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| TW201800420A (zh) | 2016-05-20 | 2018-01-01 | 艾伯維史坦森特瑞斯有限責任公司 | 抗ascl1抗體及使用方法 |
| US20190233534A1 (en) | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| GB201707779D0 (en) | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| WO2018218207A1 (en) * | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| US20190038248A1 (en) | 2017-08-04 | 2019-02-07 | Dentalaire Products Int'l | Veterinary X-ray Sensor and Boot |
| US20200063100A1 (en) * | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| CA3173213A1 (en) | 2020-03-31 | 2021-10-07 | Roland B. WALTER | Anti-cd33 antibodies and uses thereof |
-
2021
- 2021-03-31 EP EP21781573.7A patent/EP4126248A4/en active Pending
- 2021-03-31 CA CA3173205A patent/CA3173205A1/en active Pending
- 2021-03-31 US US17/907,655 patent/US12662546B2/en active Active
- 2021-03-31 JP JP2022559585A patent/JP7855521B2/ja active Active
- 2021-03-31 WO PCT/US2021/025220 patent/WO2021202770A2/en not_active Ceased
- 2021-03-31 CN CN202180025735.8A patent/CN115397515A/zh active Pending
-
2026
- 2026-04-22 JP JP2026071149A patent/JP2026123131A/ja active Pending